ReviewClinical rheumatology2020
The use of tocilizumab in the treatment of refractory eosinophilic fasciitis: a case-based review.
Review in Clinical rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Favorable clinical outcomes of biologic and targeted therapies in refractory eosinophilic fasciitis: a case-based systematic review.Rheumatology international · 2026Pooled it
- Eosinophilic Fasciitis With Overlap Connective Tissue Disease: A Diagnostic Challenge in Progressive Skin Fibrosis.Cureus · 2026Article
- Eosinophilic fasciitis.Medicina clinica · 2025Review
- Clinicopathological profile of eosinophilic fasciitis: a retrospective cohort study from a neuromuscular disorder center in China.Arthritis research & therapy · 2025Article
- Treatment and Monitoring of Eosinophilic Fasciitis.Current treatment options in rheumatology · 2025Article
- Juvenile eosinophilic fasciitis: a single center case series.Pediatric rheumatology online journal · 2024Article
- [Paraneoplastic syndromes in rheumatology].Zeitschrift fur Rheumatologie · 2023Review
- Tocilizumab in the Treatment of Eosinophilic Fasciitis: A Case Study and Review of Literature.Mediterranean journal of rheumatology · 2023Review
- Eosinophilic Fasciitis: Current and Remaining Challenges.International journal of molecular sciences · 2023Review
- Eosinophilic fasciitis (Shulman disease) with clinical, imaging and pathological correlation.BMJ case reports · 2021Article
- Eosinophilic fasciitis in a pregnant woman with corticosteroid dependence and good response to infliximab.Rheumatology international · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eosinophilic fasciitis (EF) is a rare disorder involving chronic inflammation of the fascia and connective tissue of unknown aetiology and poorly understood pathogenesis. We present the case of a 60-year-old man diagnosed with eosinophilic fasciitis with extensive cutaneous involvement and severe functional repercussion, which appeared weeks after suffering from pneumonia due to Legionella pneumophila. The patient did not experience any clinical response with high-dose corticosteroids, subcutaneous methotrexate, and intravenous immunoglobulins. Consequently, tocilizumab was initiated at 8 mg/Kg monthly achieving clinical response measured by a control MRI at the fifth dose. Response in terms of cutaneous thickness has been slower however favourable, therefore, more months of follow-up are necessary to assess the complete remission at skin level. EF treatment still constitutes a challenge, and experience with tocilizumab in the management of the disease is very limited. Through a systematic search of medical literature, we retrieved two cases describing EF treated with tocilizumab and several cases using another monoclonal antibody or Janus kinase inhibitor. We report the third case to our knowledge of the efficacy of tocilizumab in a refractory EF to corticosteroids and other immunosuppressive drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.